Abstract
BACKGROUND The aim of our study was to evaluate all lesions in the adenoma-dysplasia-cancer sequence of the colon and to examine whether the neutrophil-to-lymphocyte ratio (NLR) can distinguish polyps indicating dysplasia and cancer. MATERIAL AND METHODS A total of 397 patients who had colonoscopic polypectomy between January 2010 and December 2014 were included in our retrospective study. The patients were divided into four groups: patients with hyperplastic polyps, patients with adenomatous polyps, patients with dysplasia, and patients with cancer. The NLR was calculated as a simple ratio indicating the relationship between counts of absolute neutrophil and absolute lymphocyte. RESULTS The NLR increased in line with the adenomatous polyp-dysplasia-cancer sequence, with the highest ratio established among cancer patients (2.05 (0.27-10), 2.34 (0.83-14.70) and 3.25 (0.81-10.0), respectively). The NLR was significantly higher among cancer patients than among patients with adenomatous polyps and hyperplastic polyps (p values were 0.001 and 0.004, respectively). The lymphocyte count of cancer patients was prominently lower when compared to those in groups with adenomatous polyps and hyperplastic polyps (p values were 0.001 and 0.003, respectively). The NLR was found to be significantly higher in patients with polyps larger than 10 mm [2.71 (0.90-14.70)] when compared to those with polyps smaller than 10 mm [2.28 (0.27-11.67)] (p
Original language | English |
---|---|
Pages (from-to) | 204-211 |
Number of pages | 8 |
Journal | Annals of surgical oncology |
DOIs | |
Publication status | Published - 2017 |
Keywords
- *Adenocarcinoma
- *Adenocarcinoma/bl [Blood]
- *Adenocarcinoma/im [Immunology]
- *Adenocarcinoma/mo [Mortality]
- *Adenocarcinoma/pa [Pathology]
- *Adenocarcinoma/sc [Secondary]
- *Adenocarcinoma/th [Therapy]
- *Adenoma/ep [Epidemiology]
- *Adenoma/pa [Pathology]
- *Adenomatous Polyps/im [Immunology]
- *Adenomatous Polyps/pa [Pathology]
- *Anastomotic Leak/di [Diagnosis]
- *Antibodies
- *Antineoplastic Agents
- *Antineoplastic Agents/ae [Adverse Effects]
- *Antineoplastic Agents/tu [Therapeutic Use]
- *Antineoplastic Combined Chemotherapy Protocols/ae
- *Antineoplastic Combined Chemotherapy Protocols/tu
- *B7-H1 Antigen/an [Analysis]
- *Bevacizumab/tu [Therapeutic Use]
- *Biomarkers
- *Biomarkers/bl [Blood]
- *Blood Cell Count
- *Blood Platelets
- *Blood Platelets/cy [Cytology]
- *Blood Platelets/im [Immunology]
- *Blood Platelets/me [Metabolism]
- *Blood Platelets/pa [Pathology]
- *Body Mass Index
- *Breast Neoplasms/pa [Pathology]
- *C-Reactive Protein/an [Analysis]
- *C-Reactive Protein/me [Metabolism]
- *Camptothecin/aa [Analogs & Derivatives]
- *Carcinoembryonic Antigen/bl [Blood]
- *Carcinoembryonic Antigen/me [Metabolism]
- *Carcinoma
- *Carcinoma/bl [Blood]
- *Carcinoma/di [Diagnosis]
- *Chemoradiotherapy
- *Chemoradiotherapy/mt [Methods]
- *Chemotherapy
- *Cisplatin/ad [Administration & Dosage]
- *Colectomy
- *Colectomy/mt [Methods]
- *Colonic Neoplasms
- *Colonic Neoplasms/bl [Blood]
- *Colonic Neoplasms/dt [Drug Therapy]
- *Colonic Neoplasms/pa [Pathology]
- *Colonic Neoplasms/su [Surgery]
- *Colonic Neoplasms/th [Therapy]
- *Colonic Polyps/bl [Blood]
- *Colonic Polyps/pa [Pathology]
- *Colorectal Neoplasms
- *Colorectal Neoplasms/bl [Blood]
- *Colorectal Neoplasms/di [Diagnosis]
- *Colorectal Neoplasms/dt [Drug Therapy]
- *Colorectal Neoplasms/ep [Epidemiology]
- *Colorectal Neoplasms/et [Etiology]
- *Colorectal Neoplasms/ge [Genetics]
- *Colorectal Neoplasms/im [Immunology]
- *Colorectal Neoplasms/me [Metabolism]
- *Colorectal Neoplasms/mo [Mortality]
- *Colorectal Neoplasms/pa [Pathology]
- *Colorectal Neoplasms/pp [Physiopathology]
- *Colorectal Neoplasms/su [Surgery]
- *Colorectal Neoplasms/th [Therapy]
- *Colorectal Surgery/mo [Mortality]
- *Cytokines/bl [Blood]
- *Digestive System Surgical Procedures/sn [Statisti
- *Disease Progression
- *Drug Therapy/mt [Methods]
- *Elective Surgical Procedures
- *Embolization
- *Emergency Treatment/sn [Statistics & Numerical Da
- *Epithelial-Mesenchymal Transition
- *Esophageal Neoplasms/di [Diagnosis]
- *Esophageal Neoplasms/mo [Mortality]
- *Exercise Test
- *Exercise Tolerance/ph [Physiology]
- *Fluorouracil/tu [Therapeutic Use]
- *Glasgow Outcome Scale
- *Health Status Indicators
- *Hepatectomy
- *Hepatectomy/ae [Adverse Effects]
- *Hydrocortisone/bl [Blood]
- *Hyperplasia/pa [Pathology]
- *Inflammasomes/me [Metabolism]
- *Inflammation/bl [Blood]
- *Inflammation/di [Diagnosis]
- *Inflammation/et [Etiology]
- *Inflammation/im [Immunology]
- *Inflammation/me [Metabolism]
- *Inflammation/pa [Pathology]
- *Inflammation/pp [Physiopathology]
- *Inflammatory Bowel Diseases/et [Etiology]
- *Inflammatory Bowel Diseases/me [Metabolism]
- *Kaplan-Meier Estimate
- *Kidney Neoplasms/pa [Pathology]
- *Laparoscopy/mo [Mortality]
- *Length of Stay
- *Leukocyte Count
- *Leukocytes
- *Leukocytes/me [Metabolism]
- *Life Style
- *Liver Neoplasms/bl [Blood]
- *Liver Neoplasms/di [Diagnosis]
- *Liver Neoplasms/im [Immunology]
- *Liver Neoplasms/mo [Mortality]
- *Liver Neoplasms/sc [Secondary]
- *Liver Neoplasms/su [Surgery]
- *Liver Transplantation/mo [Mortality]
- *Lung Neoplasms/mo [Mortality]
- *Lymph Node Excision
- *Lymph Nodes/pa [Pathology]
- *Lymphocyte Count
- *Lymphocytes
- *Lymphocytes/cy [Cytology]
- *Lymphocytes/im [Immunology]
- *Lymphocytes/me [Metabolism]
- *Lymphocytes/pa [Pathology]
- *Mean Platelet Volume
- *Metabolic Syndrome/bl [Blood]
- *Metabolic Syndrome/ep [Epidemiology]
- *Metastasectomy/mt [Methods]
- *MicroRNAs/ge [Genetics]
- *Muscle
- *Muscular Diseases/et [Etiology]
- *Neoadjuvant Therapy
- *Neoadjuvant Therapy/mo [Mortality]
- *Neoplasm Recurrence
- *Neoplasms
- *Neoplasms/bl [Blood]
- *Neoplasms/th [Therapy]
- *Neoplastic Cells
- *Nephrectomy/mo [Mortality]
- *Neutrophils
- *Neutrophils/cy [Cytology]
- *Neutrophils/im [Immunology]
- *Neutrophils/me [Metabolism]
- *Neutrophils/pa [Pathology]
- *Nutrition Assessment
- *Nutritional Status
- *Patient Selection
- *Peritoneal Neoplasms/su [Surgery]
- *Platelet Count
- *Postoperative Complications
- *Postoperative Complications/di [Diagnosis]
- *Postoperative Complications/et [Etiology]
- *Postoperative Complications/im [Immunology]
- *Predictive Value of Tests
- *Preoperative Care
- *Preoperative Care/mt [Methods]
- *Preoperative Period
- *Prognosis
- *Proteins/me [Metabolism]
- *Rectal Neoplasms/bl [Blood]
- *Rectal Neoplasms/di [Diagnosis]
- *Rectal Neoplasms/dt [Drug Therapy]
- *Rectal Neoplasms/im [Immunology]
- *Rectal Neoplasms/mo [Mortality]
- *Rectal Neoplasms/pa [Pathology]
- *Rectal Neoplasms/th [Therapy]
- *Serum Albumin/an [Analysis]
- *Serum Albumin/me [Metabolism]
- *Stomach Neoplasms
- *Stomach Neoplasms/im [Immunology]
- *Surgical Wound Infection/et [Etiology]
- *Systemic Inflammatory Response Syndrome/bl [Blood
- *Systemic Inflammatory Response Syndrome/et [Etiol
- *Systemic Inflammatory Response Syndrome/pp [Physi
- *Uterine Cervical Neoplasms/th [Therapy]
- *Yttrium Radioisotopes/pd [Pharmacology]
- *gamma-Glutamyltransferase/bl [Blood]
- 80 and over
- Adenocarcinoma
- Adenocarcinoma/di [Diagnosis]
- Adenocarcinoma/im [Immunology]
- Adenocarcinoma/mo [Mortality]
- Adenocarcinoma/pa [Pathology]
- Adenocarcinoma/su [Surgery]
- Adenocarcinoma/th [Therapy]
- Adenoma/bl [Blood]
- Adenoma/pa [Pathology]
- Adenomatous Polyps/bl [Blood]
- Adjuvant
- Adjuvant/ae [Adverse Effects]
- Adjuvant/mo [Mortality]
- Adjuvant/mt [Methods]
- Adolescent
- Adult
- Age Factors
- Aged
- Anastomotic Leak/bl [Blood]
- Animals
- Antimetabolites
- Antineoplastic Agents/tu [Therapeutic Use]
- Antineoplastic Combined Chemotherapy Protocols/ae
- Antineoplastic Combined Chemotherapy Protocols/tu
- Antineoplastic/ad [Administration & Dosage]
- Area Under Curve
- Australia
- Bevacizumab
- Biological
- Biomarkers
- Biomarkers/an [Analysis]
- Biomarkers/bl [Blood]
- Biomarkers/me [Metabolism]
- Blood Cell Count
- Blood Loss
- Blood Platelets/pa [Pathology]
- Blood Sedimentation
- Body Composition
- Body Mass Index
- Breast Neoplasms/dt [Drug Therapy]
- Breast Neoplasms/im [Immunology]
- Breast Neoplasms/me [Metabolism]
- Breast/dt [Drug Therapy]
- Breast/me [Metabolism]
- Breast/mo [Mortality]
- Breast/pa [Pathology]
- C-Reactive Protein/an [Analysis]
- C-Reactive Protein/me [Metabolism]
- CA-19-9 Antigen/me [Metabolism]
- Cachexia
- Camptothecin/tu [Therapeutic Use]
- Carboplatin/ad [Administration & Dosage]
- Carcinoembryonic Antigen/bl [Blood]
- Carcinoembryonic Antigen/me [Metabolism]
- Carcinoma
- Carcinoma/dt [Drug Therapy]
- Carcinoma/mo [Mortality]
- Carcinoma/pa [Pathology]
- Case-Control Studies
- Catheter Ablation
- Cell Adhesion Molecules/ge [Genetics]
- Cell Adhesion Molecules/me [Metabolism]
- Cell Count
- Chemoradiotherapy
- Chemoradiotherapy/mt [Methods]
- Chemotherapy
- Child
- China
- China/ep [Epidemiology]
- Circulating/me [Metabolism]
- Circulating/pa [Pathology]
- Cisplatin/tu [Therapeutic Use]
- Cohort Studies
- Colectomy
- Colectomy/ae [Adverse Effects]
- Colectomy/mo [Mortality]
- Colectomy/mt [Methods]
- Colectomy/sn [Statistics & Numerical Data]
- Colon/me [Metabolism]
- Colon/pa [Pathology]
- Colon/su [Surgery]
- Colonic Neoplasms/bl [Blood]
- Colonic Neoplasms/mo [Mortality]
- Colonic Neoplasms/pa [Pathology]
- Colonic Neoplasms/su [Surgery]
- Colonic Polyps/bl [Blood]
- Colonic Polyps/di [Diagnosis]
- Colonic Polyps/pa [Pathology]
- Colonic Polyps/su [Surgery]
- Colonoscopy
- Colorectal Neoplasms/bl [Blood]
- Colorectal Neoplasms/co [Complications]
- Colorectal Neoplasms/di [Diagnosis]
- Colorectal Neoplasms/dt [Drug Therapy]
- Colorectal Neoplasms/ep [Epidemiology]
- Colorectal Neoplasms/im [Immunology]
- Colorectal Neoplasms/me [Metabolism]
- Colorectal Neoplasms/mo [Mortality]
- Colorectal Neoplasms/pa [Pathology]
- Colorectal Neoplasms/sc [Secondary]
- Colorectal Neoplasms/su [Surgery]
- Colorectal Neoplasms/th [Therapy]
- Combined Modality Therapy
- Cross-Sectional Studies
- Cyclophosphamide/ad [Administration & Dosage]
- Cytokines/im [Immunology]
- Cytoreduction Surgical Procedures
- DNA Mismatch Repair
- Demography
- Digestive System Surgical Procedures/ae [Adverse E
- Digestive System Surgical Procedures/mt [Methods]
- Disease Progression
- Disease-Free Survival
- Ductal
- Early Detection of Cancer/mt [Methods]
- Elective Surgical Procedures
- Emergency Treatment/mt [Methods]
- Epirubicin/ad [Administration & Dosage]
- ErbB-2/me [Metabolism]
- Esophageal Neoplasms/dt [Drug Therapy]
- Esophageal Neoplasms/pa [Pathology]
- Esophageal Neoplasms/su [Surgery]
- Esophagectomy
- Estrogen/me [Metabolism]
- Feasibility Studies
- Female
- Fluorouracil/ad [Administration & Dosage]
- Fluorouracil/tu [Therapeutic Use]
- Follow-Up Studies
- Forecasting
- Gastric cancer
- Gastrointestinal Microbiome
- Health Care Costs
- Hemoglobins/me [Metabolism]
- Hepatectomy
- Hepatocellular/im [Immunology]
- Hepatocellular/su [Surgery]
- Hospitalization/ec [Economics]
- Human
- Humanized/tu [Therapeutic Use]
- Humans
- Hydrocortisone/df [Deficiency]
- Hydrocortisone/me [Metabolism]
- Hyperthermia
- Hypoalbuminemia/bl [Blood]
- IgG/me [Metabolism]
- Immune System/cy [Cytology]
- Immune System/im [Immunology]
- Immune System/me [Metabolism]
- Immunological/tu [Therapeutic Use]
- Incidence
- Induced
- Inflammation
- Inflammation Mediators/bl [Blood]
- Inflammation/bl [Blood]
- Inflammation/di [Diagnosis]
- Inflammation/et [Etiology]
- Inflammation/ge [Genetics]
- Inflammation/im [Immunology]
- Inflammation/mo [Mortality]
- Inflammation/pa [Pathology]
- Inflammation/su [Surgery]
- Inflammation/th [Therapy]
- Inflammatory Bowel Diseases/co [Complications]
- Kaplan-Meier Estimate
- Kidney Neoplasms/mo [Mortality]
- Kidney Neoplasms/su [Surgery]
- Laparoscopy
- Leucovorin/tu [Therapeutic Use]
- Leukocyte Count
- Leukocyte Count/mt [Methods]
- Leukocytes/pa [Pathology]
- Lipopolysaccharide Receptors/me [Metabolism]
- Liver Neoplasms/bl [Blood]
- Liver Neoplasms/im [Immunology]
- Liver Neoplasms/mo [Mortality]
- Liver Neoplasms/sc [Secondary]
- Liver Neoplasms/su [Surgery]
- Liver Neoplasms/th [Therapy]
- Lobular/dt [Drug Therapy]
- Lobular/me [Metabolism]
- Lobular/pa [Pathology]
- Local
- Local/bl [Blood]
- Local/di [Diagnosis]
- Local/ep [Epidemiology]
- Local/im [Immunology]
- Local/mo [Mortality]
- Local/pa [Pathology]
- Local/pc [Prevention & Control]
- Local/su [Surgery]
- Local/th [Therapy]
- Logistic Models
- Longitudinal Studies
- Lung Neoplasms/sc [Secondary]
- Lung Neoplasms/th [Therapy]
- Lymph Nodes/dg [Diagnostic Imaging]
- Lymph Nodes/pa [Pathology]
- Lymph Nodes/su [Surgery]
- Lymphatic Metastasis
- Lymphocyte Count
- Lymphocytes
- Lymphocytes/im [Immunology]
- Lymphocytes/pa [Pathology]
- Lymphopenia/ci [Chemically Induced]
- Magnetic Resonance Imaging
- Male
- Malnutrition
- Middle Aged
- Models
- Monoclonal
- Monocytes/im [Immunology]
- Monocytes/me [Metabolism]
- Mononuclear/pa [Pathology]
- Morbidity
- Mortality
- Mucinous/me [Metabolism]
- Mucinous/mo [Mortality]
- Mucinous/pa [Pathology]
- Mucinous/pp [Physiopathology]
- Mucinous/sc [Secondary]
- Mucinous/su [Surgery]
- Mucinous/th [Therapy]
- Multiple Primary/im [Immunology]
- Multiple Primary/pa [Pathology]
- Multiple Primary/su [Surgery]
- Multivariate Analysis
- Muscle
- Muscular Diseases/dg [Diagnostic Imaging]
- Muscular Diseases/pa [Pathology]
- NLR
- NLR Proteins/me [Metabolism]
- Neoadjuvant Therapy
- Neoadjuvant Therapy/mt [Methods]
- Neoplasm Grading
- Neoplasm Invasiveness
- Neoplasm Invasiveness/pa [Pathology]
- Neoplasm Metastasis
- Neoplasm Recurrence
- Neoplasm Staging
- Neoplasms
- Neoplasms/di [Diagnosis]
- Neoplasms/et [Etiology]
- Neoplasms/im [Immunology]
- Neoplasms/me [Metabolism]
- Neoplasms/mo [Mortality]
- Neoplasms/pp [Physiopathology]
- Neoplasms/th [Therapy]
- Neoplastic Cells
- Neutropenia/ci [Chemically Induced]
- Neutrophil lymphocyte ratio
- Neutrophil lymphocyte ratio (NLR)
- Neutrophils
- Neutrophils/cy [Cytology]
- Neutrophils/im [Immunology]
- Neutrophils/me [Metabolism]
- Neutrophils/pa [Pathology]
- Neutrophils/ph [Physiology]
- Nomograms
- Nutrition Assessment
- Nutritional Status
- Odds Ratio
- Operative Time
- Organoplatinum Compounds/tu [Therapeutic Use]
- Outcome
- Outcome Assessment (Health Care)
- Palliative Care
- Perioperative Period
- Peritoneal Neoplasms/dt [Drug Therapy]
- Peritoneal Neoplasms/mo [Mortality]
- Phenotype
- Platelet Count
- Postoperative Complications
- Postoperative Period
- Predictive Value of Tests
- Preoperative Care
- Preoperative Period
- Preschool
- Prevalence
- Progesterone/me [Metabolism]
- Prognosis
- Propensity Score
- Proportional Hazards Models
- Prospective Studies
- ROC Curve
- Radiopharmaceuticals/pd [Pharmacology]
- Receptor
- Receptors
- Rectal Neoplasms/me [Metabolism]
- Rectal Neoplasms/mo [Mortality]
- Rectal Neoplasms/pa [Pathology]
- Rectal Neoplasms/su [Surgery]
- Rectal Neoplasms/th [Therapy]
- Rectum/me [Metabolism]
- Rectum/pa [Pathology]
- Rectum/su [Surgery]
- Recurrence
- Registries
- Remission Induction
- Renal Cell/mo [Mortality]
- Renal Cell/sc [Secondary]
- Renal Cell/su [Surgery]
- Republic of Korea/ep [Epidemiology]
- Retrospective Studies
- Risk Assessment
- Risk Assessment/mt [Methods]
- Risk Factors
- Ruptured abdominal aortic aneurysm (rAAA)
- Saliva/me [Metabolism]
- Sensitivity and Specificity
- Serum Albumin
- Serum Albumin/an [Analysis]
- Serum Albumin/me [Metabolism]
- Severity of Illness Index
- Sex Factors
- Signal Transduction
- Signet Ring Cell/me [Metabolism]
- Signet Ring Cell/mo [Mortality]
- Signet Ring Cell/sc [Secondary]
- Signet Ring Cell/th [Therapy]
- Skeletal/dg [Diagnostic Imaging]
- Skeletal/pa [Pathology]
- Solubility
- Squamous Cell/im [Immunology]
- Squamous Cell/mo [Mortality]
- Squamous Cell/pa [Pathology]
- Squamous Cell/su [Surgery]
- Squamous Cell/th [Therapy]
- Statistical
- Statistics as Topic
- Stomach Neoplasms/mo [Mortality]
- Stomach Neoplasms/su [Surgery]
- Surgical Wound Infection/ep [Epidemiology]
- Surgical/sn [Statistics & Numerical Data]
- Survival
- Survival Analysis
- Survival Rate
- Survival Rate/td [Trends]
- Systemic Inflammatory Response Syndrome/et [Etiolo
- Taxoids/ad [Administration & Dosage]
- Tegafur/ad [Administration & Dosage]
- Therapeutic/mo [Mortality]
- Time Factors
- Toll-Like Receptors/me [Metabolism]
- Tomography
- Trastuzumab/ad [Administration & Dosage]
- Treatment Outcome
- Tumor Burden
- Tumor/an [Analysis]
- Tumor/bl [Blood]
- Tumor/ge [Genetics]
- Tumor/me [Metabolism]
- Turkey
- United Kingdom/ep [Epidemiology]
- Uracil/ad [Administration & Dosage]
- Uterine Cervical Neoplasms/im [Immunology]
- Uterine Cervical Neoplasms/mo [Mortality]
- X-Ray Computed
- Young Adult
- colorectal cancer
- immune response
- inflammation
- neutrophil-to-lymphocyte ratio
- survival
- systemic neutrophil-to-lymphocyte ratio in
- the relationship to patient
- tumour biology and local
Research Beacons, Institutes and Platforms
- Manchester Cancer Research Centre